Children and Adolescent Patients with Variants in the *ATP1A3*-encoded Sodium-Potassium ATPase Alpha-3 Subunit Demonstrate an Impaired QT Response to Bradycardia and Predisposition to Sinus Node Dysfunction

Short Title: Abnormal QT and QTc Dynamics in AHC

Meredith K. Srour, BA[1]; Minu-Tshyeto K. Bidzimou, BA[1,2]; Padmapriya Muralidharan, PhD[1]; Saige M. Mitchell, BS[1]; Mary E. Moya-Mendez, MD[1]; Lauren E. Parker, BS[1]; Gabriela Reyes Valenzuela, MD[3]; Roberto Caraballo, MD[3]; Giacomo Garone, MD[4]; Federico Vigevano, MD[4]; Sarah Weckhuysen, MD PhD[5,6,7]; Charissa Millevert, MD[5,6]; Monica Troncoso, MD[8]; Mario Matamala, MD[8]; Simona Balestrini, MD PhD[9,10]; Sanjay M. Sisodiya, PhD FRCP[9]; Josephine Poole, MSc[9]; Claudio Zucca, MD[11]; Eleni Panagiotakaki, MD PhD[12]; Maria T. Papadopoulou, MD[12]; Sébile Tchaicha, MS[12,14]; Matthildi Athina Papathanasiou Terzi[12]; Marta Zawadzka, MD PhD[13]; Maria Mazurkiewicz-Bełdzińska, MD[13]; Carmen Fons, MD PhD[14]; Jennifer Anticona, MD[14]; Elisa De Grandis, MD[15,16]; Ramona Cordani, MD[15,16]; Livia Pisciotta, MD, PhD[17]; Sergiu Groppa, MD[18]; Sandra Paryjas, MD[18]; Francesca Ragona, MD[19]; Elena Mangia, RN[19]; Tiziana Granata, MD[19]; Andrey Megvinov, PhD[20]; Rosaria Vavassori, PhD[20,21,22]; Mohamad A. Mikati, MD[23]; Andrew P. Landstrom, MD, PhD[1,2#]

[1]Department of Pediatrics, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, United States.
[2]Department of Cell Biology, Duke University School of Medicine, Durham, North Carolina, United States.
[3]Hospital Nacional de Pediatría Juan P. Garrahan, Buenos Aires, Argentina
[4]Division of Neurology, Bambino Gesù Children's Hospital, Rome, Italy
[5]Department of Neurology, Antwerp University Hospital, Antwerp, Belgium
[6]Applied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
[7]Translational Neurosciences, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium
[8]Child Neurology Service, Hospital San Borja Arriarán, University of Chile, Santiago, Chile
[9]Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London WC1N 3BG and Chalfont Centre for Epilepsy, London, Bucks, United Kingdom
[10]Neuroscience Department, Meyer Children's Hospital, European Reference Network ERN EpiCARE, 50139, Florence, Italy
[11]Clinical Neurophysiology Unit, IRCCS "E. Medea", Via Don L. Monza 20, 23842 Bosisio Parini (LC), Italy
[12]Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology, University Hospitals of Lyon, Member of ERN EpiCARE, France
[13]Department of Developmental Neurology, Medical University of Gdansk, ul. Debinki 7, 80-952, Gdansk, Poland
[14]Pediatric Neurology Department, Hospital Sant Joan de Déu, Full Member of ERN EpiCare, Barcelona University, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
[15]Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
[16]Department of Neurosciences, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy
[17]Unit of Child Neuropsychiatry, ASST Fatebenefratelli Sacco, Milan, Italy
[18]Clinic of Neurology, Johannes Gutenberg University of Mainz, Mainz, Germany
[19]Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Member of ERN EpiCARE, Via Celoria 11, 20133 Milan, Italy
[20]Euro-Mediterranean Institute of Science and Technology (I.E.ME.S.T.), Palermo, Italy; Informatics Department www.iemest.eu

[21]IAHCRC International Research Consortium, Data Management www.iahcrc.net
[22]European Reference Network EpiCARE-ERN, Patient Advocacy Group (ePAG) www.epi-care.eu
[23]Department of Pediatrics, Division of Neurology, Duke University School of Medicine, Durham, North Carolina, United States.

#Corresponding Author:
Andrew P. Landstrom, MD, PhD
Duke University Medical Center
Box 2652
Durham, North Carolina, 27710
United States
Email: andrew.landstrom@duke.edu
Phone: (919) 684-3028 Fax: (919) 385-9329
Word Count: 3895

ABSTRACT

Background: Alternating hemiplegia of childhood (AHC) is a rare disorder with both neurologic and cardiac manifestations. The ATP1A3-D801N variant is associated with a pathologically short QT interval and risk of ventricular arrhythmia following bradycardia; however, the mechanism of this remains unknown. We investigated the relationship between heart rate (HR), QT, and QTc, hypothesizing that individuals with ATP1A3-D801N have abnormal, impaired shortening of QT and QTc at lower HR leading to arrhythmia predisposition.

Methods: We performed a retrospective observational study of individuals who underwent clinical evaluation, Holter monitoring, and genetic testing for AHC at Duke University Hospitals. We also compiled a group of healthy individuals as a control cohort. A larger, worldwide cohort of individuals with *ATP1A3*-related phenotypes was compiled to investigate sinus node dysfunction. Linear regression analysis was then performed.

Results: The cohort consisted of 44 individuals with *ATP1A3*-related phenotypes with 81 Holter recordings (52.27% female; mean age at first Holter 8.04 years, range 0.58 – 33 years), compared to 36 healthy individuals with 57 Holter recordings (52.78% female; mean age at first Holter 9.84 years, range 0.08 – 38 years). Individuals with ATP1A3-D801N had reduced prolongation of QT at lower HR, manifest as a significantly lower slope for HR vs QT compared to healthy ($P<0.0001$). This resulted in a significantly higher slope of the relationship for HR vs QTc compared to healthy ($P<0.0001$). Individuals with *ATP1A3*-related phenotypes and baseline QTc <350 milliseconds (ms) had increased shortening of QT and QTc at lower HR compared to those with normal QTc ($P=0.003$; $P=0.001$). Among worldwide cases, 3 out of 131 individuals with *ATP1A3*-related phenotypes required device implantation and/or had sinus pauses >4 seconds.

Conclusions: Individuals with the ATP1A3-D801N variant exhibit paradoxical shortening of QT and QTc at lower HR, which contribute to an increased risk of arrhythmias during bradycardia. This is exacerbated by an underlying risk of sinus node dysfunction.

Non-Standard Abbreviations and Acronyms

AHC: alternating hemiplegia of childhood

ATP1A3: gene encoding for the alpha-3 subunit of sodium-potassium ATPase

ATP1A3-D801N: D801N missense variant in *ATP1A3*-encoded ATP1A3

ATP1A3 Non-D801N: missense single nucleotide variants, not including D801N, in *ATP1A3*-encoded ATP1A3

ATP1A3 LOF: presumed loss of function variants in *ATP1A3*-encoded ATP1A3

ATP1A3 Neg: no pathogenic or likely pathogenic variant identified in *ATP1A3*

QTc: corrected QT interval

HR: heart rate

BPM: beats per minute

SUDEP: sudden unexplained death in epilepsy

Clinical Perspective:

What is Known:

- Individuals with ATP1A3-D801N have a short baseline QTc.
- Two individuals with AHC experienced ventricular fibrillation following bradycardia.

What the Study Adds:

- The QT and QTc shorten to a greater extent at lower heart rate in individuals with ATP1A3-D801N than in healthy individuals.
- Individuals with *ATP1A3*-related phenotypes and QTc <350ms show greater impairment of QT and QTc dynamics than those with normal QTc.
- There is low prevalence of device implantation and significant sinus pauses in individuals with *ATP1A3*-related phenotypes, with a relatively greater prevalence in those with ATP1A3-D801N.

INTRODUCTION

Individuals with abnormally fast cardiac repolarization, manifest as a shortened QT interval, are at an increased risk of atrial and ventricular arrhythmias which can be life-threatening[1-3]. As heart rate (HR) can modulate QT interval, diagnostic criteria center around a corrected QT (QTc) which measures ventricular repolarization and normalizes it to heart rate, often using Bazett's correction[4,5]. A diagnosis of short QT syndrome (SQTS) uses Gollob's criteria, a point-based diagnostic system with increasing points given for QTc <370, <350, and <330ms, respectively[6]. In addition to short QTc, SQTS can also present with sinus node dysfunction, with prior case reports describing episodes of sinus arrest and junctional rhythm[7,8]. Further, there is an emerging relationship between HR and QT response in SQTS. Prior work has shown that individuals with SQTS display blunted response of QT to changes in HR when compared to healthy individuals[9-11]. However, the genetic and mechanistic causes of SQTS are often unclear. While believed to be heritable, only a minority of patients with SQTS are genotype positive for causative genes[2,12]. Thus, there is a need to identify new genes and new mechanisms of SQTS development.

Alternating hemiplegia of childhood (AHC) is a rare condition which typically manifests prior to 18 months of age with episodic hemiplegia and/or quadriplegia, dystonia, oculomotor abnormalities, seizures, dysautonomia, and sudden unexplained death in epilepsy (SUDEP)[13,14]. We have previously found that individuals with AHC have cardiac features that are similar to those with SQTS, including a shortened QTc on electrocardiogram (ECG)[15-18] and sinus node dysfunction that may require device implantation[19,20]. Specifically, we found that individuals hosting ATP1A3-D801N, the most common missense variant among those with AHC, are uniquely predisposed to short QTc interval and ventricular arrhythmias associated with bradycardia, particularly during periods of anesthesia or sedation[15,18,21,22]. Taken together, this work suggests that SUDEP in AHC is due to the short QT phenotype; however, the link between bradycardia and arrhythmia generation remains unknown. Exploring this question will yield important new insight into SQTS, and the modulators of cardiac repolarization, more broadly.

With this in mind, we sought to investigate QT and QTc dynamics in AHC with respect to HR through linear regression analysis, which has been previously utilized for this purpose[9,23-27]. We evaluated

143 cardiac Holter recordings of individuals with AHC and healthy individuals to determine QT and QTc
144 responses to HR and expand our understanding of arrhythmogenic risk in ATP1A3-D801N. Finally, we
145 convened a worldwide cohort of AHC cases to determine the risk of sinus node dysfunction and associated
146 outcomes.
147
148 **METHODS**
149 This was a retrospective study approved by the Duke University Hospitals Institutional Review Board, IRB
150 #Pro00094341. Informed consent was waived. In addition, retrospective data on AHC patients was
151 obtained using the International Consortium for Research on AHC and all the *ATP1A3* Rare Diseases
152 (IAHCRC), according to the rules of the IAHCRC Charter. All sites had ethics board or IRB approval.
153
154 Cohorts
155 Primary Cohort
156 The primary cohort consisted of consecutively enrolled individuals seen at Duke University Hospitals who
157 had undergone clinical evaluation and genetic testing for AHC. Individuals were included if they 1) met
158 full Aicardi diagnostic criteria for AHC[13], 2) met atypical/partial AHC diagnostic criteria and, 3) were
159 diagnosed with cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural deafness (CAPOS),
160 another disorder associated with *ATP1A3* mutations[17]. Individuals were excluded if they did not have 1) a
161 reported ECG, or 2) an ambulatory Holter monitoring report using HScribe™ software. Individuals in this
162 cohort were further categorized based on genotype as follows: ATP1A3-D801N; other pathogenic or likely
163 pathogenic single nucleotide variant in *ATP1A3*, defined as ATP1A3 non-D801N; presumed loss of
164 function variant in *ATP1A3* such as deletion or splice site variant, defined as *ATP1A3* LOF; and no likely
165 pathogenic or pathogenic *ATP1A3* variant detected on genetic testing, defined as genotype negative or
166 *ATP1A3* Neg.
167
168 Healthy Cohort

169 Healthy individuals were selected for a comparison cohort if they were seen at Duke University Hospitals
170 for a cardiovascular evaluation. The following individuals were excluded: 1) elite athletes with documented
171 cardiovascular changes secondary to intense cardiovascular activity; 2) those with known congenital heart
172 disease, channelopathy, cardiomyopathy, and skeletal myopathy; 3) those with known genetic syndrome
173 with cardiac phenotype; 4) those taking cardiac medications, including antiarrhythmics; 5) those with an
174 abnormal ECG and/or echocardiogram; and 6) those with ventricular or supraventricular ectopy >1% of
175 total QRS complexes on Holter recording. All healthy individuals had undergone Holter monitoring with
176 HScribe™ software following cardiology visits for risk prediction due to identification of a genetic variant
177 associated with cardiac disease, family history of sudden cardiac arrest, cardiomyopathy, and/or
178 channelopathy, or history of arrhythmias or prolonged QT that had since resolved. Healthy individuals were
179 matched to AHC individuals based on sex and age (+/- 2 years).
180
181 IAHCRC Cohort
182 Given the rarity of AHC diagnoses, a multinational rare disease registry was established which consisted
183 of individuals from Duke University Hospitals as above, the IAHCRC, and the Baylor College of Medicine
184 (BCM). The cohort from the IAHCRC has been previously described[28]. Inclusion criteria for these
185 individuals included, 1) meeting full Aicardi diagnostic criteria for AHC as diagnosed by a neurologist[13],
186 2) meeting atypical/partial AHC diagnostic criteria, and 3) meeting criteria for other diagnoses, such as
187 rapid-onset dystonia-parkinsonism (RDP) or CAPOS, if they had a confirmed variant in *ATP1A3*[28].
188 Individuals were excluded from analysis if they 1) did not meet the inclusion criteria, 2) did not have
189 outcome data available, such as survival and pacemaker (PM) or PM/implantable cardioverter defibrillator
190 (ICD) implantation, and 3) did not have at least 1 ECG with original tracings available for re-review.
191
192 Holter Data Analysis
193 Holter data was collected from the Primary Cohort and Healthy Cohort using the HScribe™ cardiac
194 monitoring software. Holter recordings ranged in duration from 45 minutes to 24 hours. Automatically

generated minimum, mean, and maximum HR, QT, and QTc measurements over 5-minute intervals throughout the Holter recording were abstracted. QTc was calculated using Bazett's correction[5]. A linear regression analysis was performed for each Holter recording and genotype, and a line of fit equation was calculated. Automated QT or QTc measurements that appeared to be outliers on visual inspection of linear regression and were greater than 1.5 times the value of the line of fit equation for a given HR were remeasured manually using Lepeschkin's method and Bazett's correction[5,29] and were excluded if they differed. To validate the automated Holter recording measurements, >15% of total Holter recordings were manually re-evaluated by two raters blinded to genotype using Lepeschkin's method and Bazett's correction[5,29]. The average QT and QTc for every HR interval for each genotype were then assessed for interrater agreement, defined as a difference of ≤ 10% of the lower measurement, and Bland-Altman analysis was performed. If there was >10% difference between measurements, the average of both measurements was used for analysis. As a second method of validation, all ECGs for individuals in the cohort were included in a replication analysis. The HR, QT, and QTc for each ECG were manually measured by an electrophysiologist blinded to genotype. Linear regression analyses of HR vs QT and QTc for individuals grouped by genotype were then performed.

Outcomes Analysis

We used Kaplan-Meier analysis to assess freedom from composite events, defined as 1) requiring a PM or PM/ICD, or 2) having documented sinus pauses greater than 4 seconds, based on age at last follow-up. For the Primary Cohort, this age was defined as age at last cardiology visit. For the IAHCRC Cohort, last follow-up was defined as November 1, 2022, as the database was last updated through October 2022. For those who had a composite event, age was defined as when they required device implantation or first had sinus pauses greater than 4 seconds. For Holter analyses, we only included individuals with Holter data available for review.

Statistical Analysis

221 Statistical analysis was performed using both JMP Pro 17 and Prism 10. Results are reported as mean ±
222 standard deviation with 95% confidence intervals unless otherwise noted. A Kruskal-Wallis test with
223 Dunn's post-hoc multiple comparisons or Dunnet's post-hoc comparison to healthy was used for continuous
224 variables with more than two groups. Fisher's exact test was used for nominal variables with more than two
225 groups. Mann-Whitney test was used for continuous variables with two groups. Wilcoxon matched pairs
226 signed rank test was used to compare two groups with paired samples. Simple linear regression analysis
227 was modeled by the equation QT or QTc = mHR + b, where m is equivalent to slope and b is equivalent to
228 intercept. This analysis was conducted for overall linear regression for each genotype, as well as individual
229 linear regressions for each Holter recording and first diagnostic Holter recording. A mixed model was also
230 used to verify the genotype linear regression and account for repeated measurements from the same
231 individual. The HR, genotype, and interaction between HR and genotype were fixed effects, QT and QTc
232 were outcome variables, and subject number was a random effect with a residual repeated structure. Kaplan-
233 Meier analysis was compared using log-rank test. Significance was set at P= 0.05.
234
235 **RESULTS**
236 Primary Cohort Characteristics
237 To determine the relationship between cardiac repolarization time and HR, we first evaluated individuals
238 with AHC and healthy individuals recruited from Duke University Hospitals. In total, 44 individuals with
239 *ATP1A3*-related phenotypes and 36 healthy individuals were included in the Primary Cohort (**Table 1**). All
240 Holter recordings available in the HScribe™ software were utilized. Individuals with *ATP1A3*-related
241 phenotypes were grouped based on genotype as follows: ATP1A3-D801N (9 individuals, 25 Holter
242 recordings); ATP1A3 non-D801N (25 individuals, 38 Holter recordings); *ATP1A3* LOF (4 individuals, 9
243 Holter recordings); *ATP1A3* Neg (6 individuals, 9 Holter recordings). In the healthy group, 36 individuals
244 with 57 Holter recordings were included. We found no significant difference in mean age at first diagnostic
245 Holter and biological sex between genotypes (**Table 1**). Overall, <1% of data points from Holter recordings
246 were excluded.

247

248 Individuals with ATP1A3-D801N show blunted QT change to heart rate variability

249 Our group has previously shown that individuals with ATP1A3-D801N have shorter QTc on ECG
250 compared to those with other variants[15]. Similarly, in our cohort, individuals with ATP1A3-D801N had an
251 overall mean QT and QTc on Holter that were significantly lower than that of healthy individuals (302.68
252 ± 19.27 and 385.60 ± 27.95, vs 341.12 ± 32.36 and 426.96 ± 20.54, respectively; P <0.0001). Further, the
253 mean QTc for ATP1A3-D801N was significantly lower than that of *ATP1A3* LOF and *ATP1A3* Neg. We
254 then investigated HR modulation of QT interval in each group using a linear regression analysis. It is well
255 established that the QT interval increases with reduced HR and decreases with increased HR[4,30] and that the
256 QTc, which is corrected for HR, remains relatively constant across a range of HRs in healthy individuals[4,5].
257 We confirmed this observation in our healthy cohort which showed prolonged QT with slower HR and
258 normalization of HR with QTc, demonstrated by a mean slope of HR vs QT of -1.52 and a mean slope of
259 HR vs QTc of 0.22 (**Figures 1 and 2; Table 2**). Conversely, we found that individuals with ATP1A3-
260 D801N exhibited diminished QT prolongation at lower HRs (**Figure 1; Figure S1; Table S1**). Specifically,
261 we found that D801N probands had a lower mean linear regression slope than healthy individuals (-0.85 ±
262 0.46 vs -1.52 ± 0.42, respectively; P <0.0001; **Table 2**). For example, based on our model, at a mean HR
263 of 60 beats per minute (bpm), D801N probands had a QT of 335.3ms. Conversely, healthy individuals had
264 a mean QT of 396.6ms. These results were unique to individuals hosting the D801N variant. For example,
265 individuals in the ATP1A3 non-D801N, *ATP1A3* LOF, and *ATP1A3* Neg genetic subgroups showed a
266 similar QT vs HR relationship to healthy individuals (-1.24 ± 0.43, -1.41 ± 0.35, -1.41 ± 0.16, respectively,
267 vs -1.52 ± 0.42; P value not significant). Further, each of these genotype groups showed less impairment of
268 QT dynamics compared to ATP1A3-D801N (**Table 2**). To account for different numbers of Holter
269 recordings per individual, this analysis was also replicated using only the first diagnostic Holter and
270 demonstrated a similar relationship (**Figure S2; Table S2**). We then validated the automated QT
271 measurements using manual measurements with 2 independent evaluators blinded to genotype. Again, we
272 observed a blunted response of QT to lower HR in ATP1A3-D801N with strong interrater agreement (see

273 **Supplemental Results; Figures S3-S4, Table S3**). An independent validation using manual HR and
274 QT/QTc measurements from clinical ECGs blinded to genotype demonstrated a similar relationship
275 (**Figure S5**).

276 As several variables, including biological sex, can influence cardiac repolarization time[5,31], we next
277 conducted a sub-analysis to determine whether other variables might influence this finding. We found that
278 females with an *ATP1A3*-related phenotype, and those with ATP1A3 non-D801N variants, had a
279 significantly lower slope for HR vs QT compared to males, although it was a mild physiologic difference.
280 Further, there were no significant differences between male and females in all other groups (**Table S4**).
281 When analyzed by age, there was no significant difference in QT dynamics between individuals younger
282 than 10, 10–20, or older than 20 years old for ATP1A3-D801N or all *ATP1A3*-related phenotypes (**Table**
283 **S5**). Taken together, these findings suggest that individuals with ATP1A3-D801N have a blunted
284 prolongation of QT at lower HRs, while other genetic subtypes of AHC were more similar to healthy
285 individuals in their QT dynamics.

286

287 Individuals with ATP1A3-D801N show paradoxical shortening of QTc interval at lower heart rates

288 Given the diminished QT shortening with lower HRs demonstrated in the ATP1A3-D801N group, we
289 hypothesized that this group has an accentuated shortening of QTc at low HR when compared to healthy
290 individuals. Indeed, while control individuals demonstrated no significant change in QTc at lower heart
291 rates, we found that ATP1A3-D801N individuals had further shortening of the QTc (**Figure 2; Figure S6;**
292 **Table S1**), demonstrated by a greater mean slope than healthy individuals (0.80 ± 0.51 vs 0.22 ± 0.43,
293 respectively; $P < 0.0001$; **Table 2**). For example, at a heart rate of 60bpm, the QTc for ATP1A3-D801N
294 was 356.7ms compared to 415.6ms in healthy individuals. As with QT, this relationship was similar when
295 replicated using only the first diagnostic Holter recordings for each individual and upon manual
296 measurement validation (**Supplemental Results; Figures S7-S9, Tables S2 and S6**). When linear
297 regression was performed for ECGs, there was also increased shortening of QTc at lower HR for ATP1A3-
298 D801N variant-positive individuals (**Figure S10).** Further, this blunted response was seen equally in both

299 D801N-positive males and females (**Table S7**), and there was no difference in QTc dynamics based on age
300 in individuals with *ATP1A3*-related phenotypes (**Table S8**). In summary, these results suggest that the
301 blunted QT prolongation with slower HR among individuals with ATP1A3-D801N is associated with a
302 paradoxical reduction of QTc at lower HRs compared to healthy controls and all other genetic subtypes of
303 *ATP1A3*-related phenotypes. We conclude that, given the already low QTc at baseline in these individuals,
304 bradycardia causes further reduction in QTc to a markedly abnormal range, exacerbating a known
305 arrhythmic risk factor.
306
307 Individuals with QTc<350ms demonstrate blunted QT prolongation and QTc shortening with bradycardia
308 We then investigated whether the maladaptive QT and QTc response to low HR is an ATP1A3-D801N
309 specific phenomenon, or whether individuals with other *ATP1A3* variants who have short QTc at baseline
310 also have this abnormal response. To do this, we separated individuals with *ATP1A3*-related phenotypes
311 into different groups defined by their baseline QTc on diagnostic ECG. Groups were defined using Gollob's
312 criteria[6], where normal QTc was between 370-470ms, borderline short QTc was between 350-370ms, and
313 short QTc was <350ms. Seven of the 44 patients with *ATP1A3*-related phenotypes had QTc <350ms. Four
314 of these hosted ATP1A3-D801N and the other 3 hosted ATP1A3 non-D801N variants (**Table S9**). None
315 of the individuals with *ATP1A3* LOF, *ATP1A3* Neg, or healthy individuals had QTc <350ms (**Table S9**).
316 We found that those with short diagnostic QTc (<350ms) had a diminished QT prolongation response to
317 HR compared to those with normal QTc (370-470ms), and the slope of HR vs QTc in the short QTc group
318 was significantly greater than that of the normal QTc group (**Figure 3; Table S9**). When separated by
319 specific genotype, there was greater impairment of HR vs QT dynamics in ATP1A3-D801N than in
320 ATP1A3 non-D801N for those with QTc <350ms. However, within each genotype, there was no significant
321 difference in QT or QTc dynamics when grouped by baseline QTc (see **Supplemental Results; Tables**
322 **S10-S11**). Taken together, we found that presence of short QTc of <350ms on diagnostic ECG for all
323 *ATP1A3*-related phenotypes is associated with greater impairment of QT and QTc dynamics. While this
324 effect was independent of genotype, most patients with QTc <350 hosted the ATP1A3-D801N variant.

325

326 Individuals with *ATP1A3* variants are predisposed to significant sinus node dysfynction

327 Given the association between bradycardia and QTc shortening, we next determined whether patients
328 hosting *ATP1A3* variants were at increased risk of sinus node dysfunction[19]. To do this, we leveraged a
329 large, multinational registry of individuals with AHC and *ATP1A3* genetic variants. The cohort was
330 comprised of 131 individuals who met our inclusion/exclusion criteria: the same 44 individuals from Duke
331 University Medical Center, 86 individuals from the IAHCRC, and 1 individual from BCM previously
332 described in the literature[15]. Of these additional 87 individuals, 31 had available Holter recording
333 measurements. Additional demographic characteristics for individuals from the IAHCRC and BCM are
334 detailed in **Table S12**. We found no difference in sex or age representation among the genetic subgroups
335 (**Table S12**). Individuals with ATP1A3-D801N reached an average maximum HR during Holter
336 monitoring that was significantly lower than healthy individuals (153.94 ± 18.80 vs 176.21 ± 22.52; P
337 <0.0001). Otherwise, there was no significant difference in average minimum HR, mean HR, and
338 ventricular and supraventricular ectopy burden between any of the groups and healthy individuals (**Table**
339 **3**). We identified 3 out of 131 individuals who met the composite endpoint of implantation of a PM or
340 PM/ICD or documented sinus pause, with a mean age at follow-up of 15.62 years (maximum of 50 years).
341 Among them, 2 out of 3 hosted the D801N variant and the third hosted ATP1A3-S137F. For healthy
342 individuals, *ATP1A3* LOF, and *ATP1A3* Neg, no individuals met the composite endpoint during the follow-
343 up period. This yielded a calculated composite event rate of 0.15%/year/individual for the entire cohort,
344 with a D801N-positive event rate of 0.38%/year/individual (**Figure 4**). Thus, leveraging the largest
345 international cohort to date to explore this endpoint, we concluded that, although the frequency of
346 significant sinus node dysfunction is low, individuals hosting the D801N variant have a greater
347 predisposition to developing it compared to other genetic subtypes.

348

349 Flunarizine may exacerbate the blunted QT response to bradycardia but does not worsen sinus node
350 dysfunction

351 Given that the standard of care for treatment of AHC involves the use of flunarizine[32,33], a T-type calcium
352 channel blocker, we next explored whether use of flunarizine was associated with exacerbation of the
353 cardiac phenotype observed, since its impact on the heart is unknown. Of the 131 individuals included, 90
354 were taking flunarizine and there was no significant difference between flunarizine use and the genetic
355 subtypes (**Table S13**). Among them, flunarizine use was not associated with changes in average minimum,
356 mean, or maximum HR for any genotype group when compared to those who were not taking flunarizine
357 (**Table S13**). When exploring the relationship between QT/QTc dynamics and flunarizine, we did find that
358 the overall slope for HR vs QTc was significantly greater for individuals with all *ATP1A3*-related
359 phenotypes taking flunarizine than for those who were not (**Table S13**). Specifically, we found that at a HR
360 of 60 bpm, the mean QTc was 376.97ms among those taking flunarizine versus 402.4ms among those not
361 taking flunairzine. This suggests that flunarizine might be associated with impairment of QT prolongation
362 during periods of bradycardia; however, the physiologic and clinical relevance of this finding is uncertain.
363 When separated by biological sex, the mean slope for HR vs QT among individuals taking flunarizine was
364 significantly lower in females than in males. At 60bpm, the mean QT in females taking flunarizine was
365 350.9ms versus 366.1ms in males, suggesting that flunarizine shortening of the QT interval might be
366 exacerbated in female patients (**Table S14**). This sex-bias was also observed for all patients with *ATP1A3*-
367 related phenotypes, regardless of flunarizine use (**Tables S4 and S7**). There was no difference in QT/QTc
368 dynamics based on flunarizine use for males (**Table S15**). However, females taking flunarizine had a
369 significantly lower slope for HR vs QT than females who were not not (**Table S16**). Taken together,
370 flunarizine may statistically impair QT dynamics during lower HR among specific subgroups of patients,
371 particularly among female individuals. Despite this statistical difference, the overall physiologic impact of
372 flunarizine on the heart remains unclear. This is particularly important as there is a clear role for flunarizine
373 in treating the neurologic manifestations of *ATP1A3*-related disease.
374
375 **DISCUSSION**

376 This study expands our understanding of arrhythmia risk in individuals with *ATP1A3*-related diseases, such
377 as AHC. In healthy individuals, the QT interval adapts to changes in HR by shortening when the HR
378 increases and lengthening when the HR decreases[4,30]. When correted by HR, the QTc remains relatively
379 fixed across a range of HRs among healthy individuals. We demonstrate that individuals with the ATP1A3-
380 D801N variant show impairment of this relationship with decreased prolongation of QT at lower HR,
381 similar to individuals diagnosed with SQTS[9,10]. This phenomenon has previously been described as
382 deceleration-dependent QT interval shortening[34,35]. One mechanistic explanation for this finding is that
383 increased acetylcholine inhibits the proper prolongation of QT when the HR slows[34,36]. Additionally,
384 inhibition of autonomic activity has been shown to cause impairment of QT dynamics[37]. Dysautonomia is
385 a minor diagnostic criterion for AHC[13] and could therefore be an explanation for the findings we describe
386 in ATP1A3-D801N. Overall, we uncover a potential novel mechanism of QT modulation that could
387 increase arrhythmia risk at lower HR, which seems to be based in a myocardial defect. However, the specific
388 details of how autonomic alterations further exacerbate risk is still unknown.
389
390 Correcting QT for HR can be done through a variety of different means[5,38-40]. Previous work has
391 demonstrated limitations to Bazett's correction in effectively normalizing the QTc during bradycardia and
392 tachycardia[41,42]. Importantly, we found that Bazett's correction held for all healthy individual HR ranges,
393 which include most HR ranges in our disease cohorts. Specifically, the slope of mean HR vs mean QTc for
394 healthy individuals was close to zero, indicating effective normalization of the QT for differences in HR
395 (**Figure 2**). From this, we ultimately concluded that the automated Bazett's correction formula was suitable
396 for correcting QT in all groups. In addition, we assessed association of changes in QT and QTc dynamics
397 with factors such as biological sex, age, and flunarizine use. While we found a difference in HR vs QT
398 between males and females, there was no difference in HR vs QTc, suggesting that HR variation might
399 manifest as a difference in QT responsiveness that subsides with QT correction for HR. Age did not seem
400 to have an effect, whereas flunarizine use showed a small effect on HR vs QTc dynamics. However, we see
401 no clear evidence that flunarizine negatively impacts the heart. Moreover, it is the medication of choice for

402 alleviation of neurologic symptoms in AHC, therefore the known benefits are significantly greater than any
403 harms.
404
405 Given the finding that individuals with ATP1A3-D801N have short QTc at baseline[15,16], which is a known
406 arrhythmia risk[1-3], we saught to determine the affect of heart rate on this QT abnormality. We found that
407 individuals with *ATP1A3*-related phenotypes who also had a short baseline QTc demonstrated impairment
408 of normal QT dyanmics with changing in HR, particularly during periods of bradycardia. This results in a
409 shortening of the QTc at lower HR, which exacerbates the short QT phenotype further. It is likely that this
410 is the proarrhythmic trigger for many patients who have had a life-threatening arrhythmic event with
411 *ATP1A3*-related disease. As such, it is critical that patients with AHC, and anyone with an *ATP1A3*
412 mutation, are evaluated by an electrophysiology and cardiovascular genetic specialist to determine their
413 QT/QTc at baseline. This clincal evaluation, when combined with genetic risk assessment, is key to
414 determining the risk for arrhythmias. Furthermore, with increasing knowledge of the cardiac manifestations
415 of AHC, questions arise as to whether these individuals are at risk of sinus node dysfunction requiring PM
416 or ICD implantation. Analysis of our combined cohort shows that sinus node dysfunction is uncommon,
417 with few individuals requiring a device or experiencing significant sinus pauses. While the risk is low,
418 events can be severe when they do occur, and our results indicate a greater event rate in those with ATP1A3-
419 D801N. Thus, it is crucial to universally check and routinely monitor sinus node dysfunction in these
420 individuals through ambulatory monitoring. Further, as sinus bradycardia resulting from sinus node
421 dysfunction might compound the risk in patients with the D801N variant and short QT, this may represent
422 another pro-arrhythmic variable.
423
424 We acknowledge limitations to our study design and methodology. As this is a retrospective study, it is
425 unclear if abnormal QT and QTc dynamics with decreasing HR are directly responsible for arrhythmias in
426 individuals with ATP1A3-D801N. Future directions include exploring rate dependency in human induced
427 pluripotent stem cell cardiomyocytes (iPSC-CMs) from individuals with ATP1A3-D801N to better

428 characterize this mechanism. Additionally, AHC is a rare disease and our cohort is small. As a result, we
429 may be underpowered to detect certain differences. However, this is the largest study to date of Holter
430 recordings from patients with AHC across a multinational registry. Finally, rather than using beat-to-beat
431 data, our study utilizes five-minute averages of HR, QT, and QTc provided by the Holter monitoring
432 software. Although this provides us with less data than would otherwise be available, we were still able to
433 detect a significant difference in relationships between ATP1A3-D801N and healthy.
434

435 **CONCLUSIONS**

436 Overall, our findings support the idea that AHC, and specifically the ATP1A3-D801N variant, can manifest
437 as a cardiac phenotype resembling SQTS. It is important to advise individuals with ATP1A3-D801N,
438 particularly those with very short baseline QTc on ECG, of the risk of arrhythmia with slowed HR, such as
439 during sedation or anesthesia. Currently, there is no treatment for abnormal QT and QTc dynamics,
440 although quinidine has been proposed for patients with SQTS[10]. For now, cardiac monitoring during periods
441 of possible low HR is advised.
442

443 **ACKNOWLEDGEMENTS**

444 Thank you to all contributors to the IAHCRC. Dr. Andrew Landstrom had full access to all the data in the
445 study and takes responsibility for data integrity and accuracy of data analysis.
446

447 **SOURCES OF FUNDING**

448 MKB is supported by The Paul Gillette PACES Research Grant and by National Institute of Health (NIH)
449 T32 GM007171. APL is supported by National Institutes of Health (R01-HL160654, R01-HL166217),
450 Doris Duke Charitable Foundation (CSDA-2020098), John Taylor Babbitt Foundation, The Hartwell
451 Foundation, Additional Ventures, Y.T. and Alice Chen Pediatric Genetics and Genomics Research Center.
452
453

454 **DISCLOSURES**

455 MAM has intellectual property interest in gene therapy for *ATP1A3*-related disease pending patent
456 application.

457

458 **SUPPLEMENTAL MATERIAL**

459 Tables S1–S16

460 Figures S1-S10

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

REFERENCES

1. Gussak I, Brugada P, Brugada J, Wright RS, Kopecky SL, Chaitman BR, Bjerregaard P. Idiopathic Short QT Interval:A New Clinical Syndrome? *Cardiology*. 2001;94:99-102. doi: 10.1159/000047299
2. Giustetto C, Schimpf R, Mazzanti A, Scrocco C, Maury P, Anttonen O, Probst V, Blanc J-J, Sbragia P, Dalmasso P, et al. Long-Term Follow-Up of Patients With Short QT Syndrome. *Journal of the American College of Cardiology*. 2011;58:587-595. doi: https://doi.org/10.1016/j.jacc.2011.03.038
3. Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R, Grossi S, Richiardi E, Borggrefe M. Short QT Syndrome. *Circulation*. 2003;108:965-970. doi: doi:10.1161/01.CIR.0000085071.28695.C4
4. Seed WA, Noble MI, Oldershaw P, Wanless RB, Drake-Holland AJ, Redwood D, Pugh S, Mills C. Relation of human cardiac action potential duration to the interval between beats: implications for the validity of rate corrected QT interval (QTc). *Br Heart J*. 1987;57:32-37. doi: 10.1136/hrt.57.1.32
5. Bazett H. An analysis of the time-relations of. *Heart*. 1920;7:353.
6. Gollob MH, Redpath CJ, Roberts JD. The Short QT Syndrome: Proposed Diagnostic Criteria. *Journal of the American College of Cardiology*. 2011;57:802-812. doi: https://doi.org/10.1016/j.jacc.2010.09.048
7. Ploneda-Valencia RG, Ortiz-Solis WA, Ruiz-Gonzalez G, Santiago-Garcia AK, Rivera-Rodríguez L, Nava-Townsend S, Márquez MF, Levinstein-Jacinto M. Supraventricular tachyarrhythmia and sinus node dysfunction as a first manifestation of short QT syndrome in a pediatric patient. Case Report. *J Electrocardiol*. 2022;74:146-153. doi: 10.1016/j.jelectrocard.2022.08.010
8. Righi D, Silvetti MS, Drago F. Sinus bradycardia, junctional rhythm, and low-rate atrial fibrillation in Short QT syndrome during 20 years of follow-up: three faces of the same genetic problem. *Cardiology in the Young*. 2016;26:589-592. doi: 10.1017/S1047951115001432
9. Giustetto C, Scrocco C, Schimpf R, Maury P, Mazzanti A, Levetto M, Anttonen O, Dalmasso P, Cerrato N, Gribaudo E, et al. Usefulness of exercise test in the diagnosis of short QT syndrome. *Europace*. 2015;17:628-634. doi: 10.1093/europace/euu351
10. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R, Hong K, Bauersfeld U, Gaita F, Borggrefe M. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. *J Cardiovasc Electrophysiol*. 2005;16:54-58. doi: 10.1046/j.1540-8167.2005.04470.x
11. Redpath CJ, Green MS, Birnie DH, Gollob MH. Rapid genetic testing facilitating the diagnosis of short QT syndrome. *Can J Cardiol*. 2009;25:e133-135. doi: 10.1016/s0828-282x(09)70077-7
12. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM, Brugada J, Pollevick GD, Wolpert C, et al. Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG. *Circulation*. 2004;109:30-35. doi: doi:10.1161/01.CIR.0000109482.92774.3A
13. Mikati MA, Panagiotakaki E, Arzimanoglou A. Revision of the diagnostic criteria of alternating hemiplegia of childhood. *Eur J Paediatr Neurol*. 2021;32:A4-a5. doi: 10.1016/j.ejpn.2021.05.004
14. Panagiotakaki E, Gobbi G, Neville B, Ebinger F, Campistol J, Nevšímalová S, Laan L, Casaer P, Spiel G, Giannotta M, et al. Evidence of a non-progressive course of alternating

527 hemiplegia of childhood: study of a large cohort of children and adults. *Brain*.
528 2010;133:3598-3610. doi: 10.1093/brain/awq295
529 15. Moya-Mendez ME, Ogbonna C, Ezekian JE, Rosamilia MB, Prange L, Uz Cdl, Kim JJ,
530 Howard T, Garcia J, Nussbaum R, et al. ATP1A3-Encoded Sodium-Potassium ATPase
531 Subunit Alpha 3 D801N Variant Is Associated With Shortened QT Interval and
532 Predisposition to Ventricular Fibrillation Preceded by Bradycardia. *Journal of the*
533 *American Heart Association*. 2021;10:e019887. doi: doi:10.1161/JAHA.120.019887
534 16. Jaffer F, Avbersek A, Vavassori R, Fons C, Campistol J, Stagnaro M, De Grandis E,
535 Veneselli E, Rosewich H, Gianotta M, et al. Faulty cardiac repolarization reserve in
536 alternating hemiplegia of childhood broadens the phenotype. *Brain*. 2015;138:2859-2874.
537 doi: 10.1093/brain/awv243
538 17. Masoud M, Prange L, Wuchich J, Hunanyan A, Mikati MA. Diagnosis and Treatment of
539 Alternating Hemiplegia of Childhood. *Current Treatment Options in Neurology*.
540 2017;19:8. doi: 10.1007/s11940-017-0444-7
541 18. Heinzen EL, Swoboda KJ, Hitomi Y, Gurrieri F, Nicole S, de Vries B, Tiziano FD,
542 Fontaine B, Walley NM, Heavin S, et al. De novo mutations in ATP1A3 cause alternating
543 hemiplegia of childhood. *Nat Genet*. 2012;44:1030-1034. doi: 10.1038/ng.2358
544 19. Balestrini S, Mikati MA, Alvarez-Garcia-Roves R, Carboni M, Hunanyan AS, Kherallah
545 B, McLean M, Prange L, De Grandis E, Gagliardi A, et al. Cardiac phenotype in
546 ATP1A3-related syndromes: A multicenter cohort study. *Neurology*. 2020;95:e2866-
547 e2879. doi: 10.1212/WNL.0000000000010794
548 20. Novy J, McWilliams E, Sisodiya SM. Asystole in alternating hemiplegia with de novo
549 ATP1A3 mutation. *European Journal of Medical Genetics*. 2014;57:37-39. doi:
550 https://doi.org/10.1016/j.ejmg.2013.11.003
551 21. Parker LE, Wallace K, Thevathasan A, Funk E, Pratt M, Thamby J, Tran L, Prange L,
552 Uchitel J, Boggs A, et al. Characterization of sedation and anesthesia complications in
553 patients with alternating hemiplegia of childhood. *European journal of paediatric*
554 *neurology : EJPN : official journal of the European Paediatric Neurology Society*.
555 2022;38:47-52. doi: 10.1016/j.ejpn.2022.03.007
556 22. Thamby J, Prange L, Boggs A, Subei MO, Myers C, Uchitel J, ElMallah M, Bartlett-Lee
557 B, Riviello JJ, Mikati MA. Characteristics of non-sleep related apneas in children with
558 alternating hemiplegia of childhood. *Eur J Paediatr Neurol*. 2024;48:101-108. doi:
559 10.1016/j.ejpn.2023.12.002
560 23. Kligfield P, Lax KG, Okin PM. QT interval-heart rate relation during exercise in normal
561 men and women: Definition by linear regression analysis. *Journal of the American*
562 *College of Cardiology*. 1996;28:1547-1555. doi: https://doi.org/10.1016/S0735-
563 1097(96)00351-8
564 24. Tavernier R, Jordaens L, Haerynck F, Derycke E, Clement DL. Changes in the QT
565 interval and its adaptation to rate, assessed with continuous electrocardiographic
566 recordings in patients with ventricular fibrillation, as compared to normal individuals
567 without arrhythmias. *Eur Heart J*. 1997;18:994-999. doi:
568 10.1093/oxfordjournals.eurheartj.a015389
569 25. Merri M, Moss AJ, Benhorin J, Locati EH, Alberti M, Badilini F. Relation between
570 ventricular repolarization duration and cardiac cycle length during 24-hour Holter
571 recordings. Findings in normal patients and patients with long QT syndrome. *Circulation*.
572 1992;85:1816-1821. doi: doi:10.1161/01.CIR.85.5.1816

26. Larroude CE, Jensen BT, Agner E, Toft E, Torp-Pedersen C, Wachtell K, Kanters JK. Beat-to-beat QT dynamics in paroxysmal atrial fibrillation. *Heart Rhythm*. 2006;3:660-664. doi: https://doi.org/10.1016/j.hrthm.2006.02.021
27. Magnano AR, Holleran S, Ramakrishnan R, Reiffel JA, Bloomfield DM. Autonomic nervous system influences on qt interval in normal subjects. *Journal of the American College of Cardiology*. 2002;39:1820-1826. doi: doi:10.1016/S0735-1097(02)01852-1
28. Moya-Mendez ME BM, Zhang Z, Ezekian JE, Perelli RM, Parker LE, Prange L, Boggs A, et al. ATP1A3 Variants are Associated with Variably Penetrant Short QT and Lethal Ventricular Arrhythmias. *In submission* 2024.
29. LEPESCHKIN E, SURAWICZ B. The Measurement of the Q-T Interval of the Electrocardiogram. *Circulation*. 1952;6:378-388. doi: doi:10.1161/01.CIR.6.3.378
30. Ahnve S. Correction of the QT interval for heart rate: review of different formulas and the use of Bazett's formula in myocardial infarction. *Am Heart J*. 1985;109:568-574. doi: 10.1016/0002-8703(85)90564-2
31. Merri M, Benhorin J, Alberti M, Locati E, Moss AJ. Electrocardiographic quantitation of ventricular repolarization. *Circulation*. 1989;80:1301-1308. doi: 10.1161/01.cir.80.5.1301
32. Mikati MA, Kramer U, Zupanc ML, Shanahan RJ. Alternating hemiplegia of childhood: clinical manifestations and long-term outcome. *Pediatr Neurol*. 2000;23:134-141. doi: 10.1016/s0887-8994(00)00157-0
33. Casaer P, Azou M. Flunarizine in alternating hemiplegia in childhood. *Lancet*. 1984;2:579. doi: 10.1016/s0140-6736(84)90794-3
34. Gussak I, Liebl N, Nouri S, Bjerregaard P, Zimmerman F, Chaitman BR. Deceleration-dependent shortening of the QT interval: a new electrocardiographic phenomenon? *Clin Cardiol*. 1999;22:124-126. doi: 10.1002/clc.4960220213
35. Takahashi N, Ito M, Ishida S, Nakagawa M, Hara M, Saikawa T, Sakata T. Paradoxically shortened QT interval after a prolonged pause. *Pacing Clin Electrophysiol*. 1998;21:1476-1479. doi: 10.1111/j.1540-8159.1998.tb00221.x
36. DiFrancesco D, Ducouret P, Robinson RB. Muscarinic Modulation of Cardiac Rate at Low Acetylcholine Concentrations. *Science*. 1989;243:669-671. doi: doi:10.1126/science.2916119
37. Cappato R, Alboni P, Codecà L, Guardigli G, Toselli T, Antonioli GE. Direct and autonomically mediated effects of oral quinidine on RR/QT relation after an abrupt increase in heart rate. *J Am Coll Cardiol*. 1993;22:99-105. doi: 10.1016/0735-1097(93)90822-i
38. FRIDERICIA LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. *Acta Medica Scandinavica*. 1920;53:469-486. doi: https://doi.org/10.1111/j.0954-6820.1920.tb18266.x
39. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). *American Journal of Cardiology*. 1992;70:797-801. doi: 10.1016/0002-9149(92)90562-D
40. Hodges M. Bazett's QT correction reviewed-Evidence that a linear QT correction for heart is better. In: *Journal of the American College of Cardiology*. 1983:694.
41. Luo S, Michler K, Johnston P, Macfarlane PW. A comparison of commonly used QT correction formulae: The effect of heart rate on the QTc of normal ECGs. *Journal of Electrocardiology*. 2004;37:81-90. doi: https://doi.org/10.1016/j.jelectrocard.2004.08.030

42. MALIK M, HNATKOVA K, BATCHVAROV V. Differences Between Study-Specific and Subject-Specific Heart Rate Corrections of the QT Interval in Investigations of Drug Induced QTc Prolongation. *Pacing and Clinical Electrophysiology*. 2004;27:791-800. doi: https://doi.org/10.1111/j.1540-8159.2004.00530.x

TABLES

Table 1. Primary cohort characteristics.

	Healthy	*ATP1A3*-Related Phenotype*	ATP1A3-D801N	ATP1A3 Non-D801N	*ATP1A3* LOF †	*ATP1A3* Neg ‡	P value
Number of Individuals	36	44	9	25	4	6	
Number of Holter Recordings	57	81	25	38	9	9	
Sex (% F)	52.78	52.27	55.56	52.00	50.00	50.00	>0.9999
Mean Age at First Holter (SD)	9.84 (7.94)	8.04 (8.50)	4.28 (4.93)	9.78 (10.26)	3.23 (1.91)	9.67 (3.50)	0.16

*Includes individuals with a formal diagnosis of AHC (n=37) or CAPOS (n=1), those who did not meet full criteria for AHC but were found to host an *ATP1A3* variant (n=5), and one individual with no variant in *ATP1A3* who did not meet full criteria for AHC (n=1). †Includes individuals with deletion (n=3) or splice site variant in *ATP1A3* (n=1). ‡Includes individuals with no pathogenic or likely pathogenic variant in *ATP1A3* identified (n=6). P values were calculated using Fisher's exact test or Kruskal-Wallis test. LOF, loss of function variant; Neg, genotype negative.

Table 2. Mean slope of linear regression for HR versus QT and QTc, compared by genotype.

	Healthy	ATP1A3-D801N	ATP1A3 Non-D801N	*ATP1A3* LOF	*ATP1A3* Neg	P value
n	57	25	38	9	9	
Mean Slope HR vs QT	-1.52 ± 0.42 (-1.63 – -1.41)	-0.85 ± 0.46 (-1.03 – -0.67)	-1.24 ± 0.43 (-1.37 – -1.10)	-1.41 ± 0.35 (-1.64 – -1.19)	-1.41 ± 0.16 (-1.52 – -1.30)	<0.0001*
Mean Slope HR vs QTc	0.22 ± 0.43 (0.11 – 0.33)	0.80 ± 0.51 (0.60 – 1.00)	0.52 ± 0.46 (0.38 – 0.67)	0.20 ± 0.50 (-0.13 – 0.53)	0.32 ± 0.22 (0.18 – 0.47)	<0.0001*

*Healthy compared to ATP1A3-D801N, using Kruskal-Wallis test with Dunnet's post-hoc comparison to healthy. Values listed as mean ± SD (95% confidence interval). HR, heart rate; QTc, corrected QT; LOF, loss of function variant; Neg, genotype negative.

Table 3. Holter recording characteristics for all individuals from primary and IAHCRC cohorts.

	Healthy	ATP1A3-D801N	ATP1A3 Non-D801N	*ATP1A3* LOF	*ATP1A3* Neg	P value
Number of Individuals (Holter recordings)	36 (57)	19 (36)	47 (58)	5 (10)	7 (10)	
Sex (% Female)	52.78	57.89	53.19	60.00	57.14	0.98
Mean Age at First Holter (SD)	9.84 (7.94)	13.75 (12.58)	10.98 (10.16)	5.35 (5.02)	12.85 (9.00)	0.44
Minimum HR (SD)	57.18 (8.30)	51.39 (7.48)	55.72 (9.84)	55.80 (8.92)	59.60 (5.38)	0.03
Mean HR (SD)	95.61 (6.53)	92.54 (12.98)	93.95 (16.80)	104.60 (10.12)	94.90 (8.74)	0.18
Maximum HR (SD)	176.21 (22.52)	153.94 (18.80)	159.05 (19.84)	166.70 (17.11)	168.10 (16.67)	**<0.0001**
Longest RR (SD)	1.26 (0.22)	1.57 (0.48)	1.30 (0.24)	1.48 (0.61)	1.28 (0.21)	**0.008**
VE/Hour	0.50 (3.29)	0.00* (0.08)	0.51 (3.55)	0.37 (1.10)	0.00 (0.00)	0.11
SVE/Hour	0.12 (0.24)	1.65 (7.25)	2.62 (14.38)	0.22 (0.71)	0.034 (0.048)	0.09

Heart rates are listed in beats per minute (BPM), RR is listed in seconds. *Listed as median (interquartile range), as one individual had 1102 VE per hour (23157 total). P value calculated with Fisher's exact test or Kruskal-Wallis test with Dunn's post-hoc multiple comparisons. HR, heart rate; VE, ventricular ectopy; SVE, supraventricular ectopy; LOF, loss of function variant; Neg, genotype negative.

FIGURES

Figure 1. ATP1A3-D801N is associated with blunted response of QT to lower HR compared to healthy. Linear regression analysis of mean HR versus mean QT over five-minute intervals throughout each Holter recording for individuals in the primary and healthy cohorts. Colored points represent individual data points for all Holter recordings included in each genotype group. Solid line represents overall linear regression line of fit. m represents slope of the line of fit equation. A. Healthy cohort (n=57), QT= -1.64HR + 501.40; R^2= 0.70. B. ATP1A3-D801N subgroup (n=25), QT= -0.79HR + 381.50; R^2= 0.32. C. ATP1A3 non-D801N subgroup (n=38), QT= -1.27HR + 445.10; R^2= 0.45. D. *ATP1A3* LOF subgroup (n=9), QT= -1.28HR + 465.50; R^2= 0.61. E. *ATP1A3* Neg subgroup (n=9), QT= -1.44HR + 483.80; R^2= 0.80. F. Overall lines of fit for each of the respective subgroups. Blue, healthy; black, ATP1A3-D801N; red, ATP1A3 non-D801N; purple, *ATP1A3* LOF; orange, *ATP1A3* Neg.

Figure 2. ATP1A3-D801N is associated with increased shortening of QTc at lower HR compared to healthy. Linear regression analysis of mean heart rate versus mean QTc over five-minute intervals throughout Holter recording for individuals in the primary and healthy cohorts. Colored points represent individual data points for all Holter recordings included in each genotype group. Solid line represents overall linear regression line of fit. m represents slope of the line of fit equation. A. Healthy (n=57), QTc= 0.06HR + 421.80; R^2= 0.0023. B. ATP1A3-D801N (n=25), QTc= 0.96HR + 291.40; R^2= 0.30. C. ATP1A3 non-D801N (n=38), QTc= 0.42HR + 362.10; R^2= 0.055. D. ATP1A3 LOF (n=9), QTc= 0.41HR + 390.40; R^2= 0.083. E. ATP1A3 Neg (n=9), QTc= 0.28HR + 406.30; R^2= 0.093. F. Lines of fit for all groups. Blue, healthy; black, ATP1A3-D801N; red, ATP1A3 non-D801N; purple, *ATP1A3* LOF; orange, *ATP1A3* Neg.

Figure 3. Short baseline QTc is associated with greater impairment of QT and QTc dynamics. Each colored line represents the linear regression for Holter recordings from individuals in the primary and

healthy cohorts with a given baseline QTc on ECG. A. Mean HR versus mean QT for Holter recordings from individuals with *ATP1A3*-related phenotypes (n=81) compared to healthy patients (n=57). B. Mean HR versus mean QTc for Holter recordings from individuals with *ATP1A3*-related phenotypes (n=81) compared to healthy (n=57). Black, <350ms (n=16); red, 350-370ms (n=15); purple, 370-470ms (n=50); blue, healthy, all 370-470ms (n=57).

Figure 4. ATP1A3-D801N is associated with sinus node dysfunction. A. Kaplan-Meier analysis of freedom from composite events versus age of event in individuals from primary and IAHCRC cohorts (n=131), as compared to those from the healthy cohort (n=36). Tick marks represent censored individuals. Bars represent 95% confidence intervals. No significant difference between healthy and *ATP1A3*-related phenotype using log-rank test (P = 0.57). B. Characteristics of individuals who had composite events. PM, pacemaker; ICD, implantable cardioverter defibrillator.


A
Healthy Mean QT (ms)
m = -1.64
Mean HR (bpm)
B
ATP1A3-D801N Mean QT (ms)
m = -0.79
Mean HR (bpm)
C
ATP1A3 Non-D801N Mean QT (ms)
m = -1.27
Mean HR (bpm)
Healthy
ATP1A3-D801N
ATP1A3 Non-D801N
ATP1A3 LOF
ATP1A3 Neg
D
ATP1A3 LOF Mean QT (ms)
m = -1.28
Mean HR (bpm)
E
ATP1A3 Neg Mean QT (ms)
m = -1.44
Mean HR (bpm)
F
All Groups Mean QT (ms)
Mean HR (bpm)


A
Healthy Mean QTc (ms)
600
400
200
m = 0.06
50
100
150
200
Mean HR (bpm)
B
ATP1A3-D801N Mean QTc (ms)
600
400
200
m = 0.96
50
100
150
200
Mean HR (bpm)
C
ATP1A3 Non-D801N Mean QTc (ms)
600
400
200
m = 0.42
50
100
150
200
Mean HR (bpm)
Healthy
ATP1A3-D801N
ATP1A3 Non-D801N
ATP1A3 LOF
ATP1A3 Neg
D
ATP1A3 LOF Mean QTc (ms)
600
400
200
m = 0.41
50
100
150
200
Mean HR (bpm)
E
ATP1A3 Neg Mean QTc (ms)
600
400
200
m = 0.28
50
100
150
200
Mean HR (bpm)
F
All Groups Mean QTc (ms)
600
400
200
50
100
150
200
Mean HR (bpm)


A
Mean QT (ms)
500
400
300
200
100
0
0
50
100
150
200
Mean HR (bpm)
B
Mean QTc (ms)
500
400
300
200
100
0
0
50
100
150
200
Mean HR (bpm)
Healthy
370-470
350-370
<350

A



B

Age at Event (y)	Genotype	Composite Event
4.5	ATP1A3-D801N	Sinus pauses >4s, cardiac arrest
23	ATP1A3-S137F	PM for episodes of sinus arrest
26	ATP1A3-D801N	Sinus pauses >4s, PM/ICD for sinus node dysfunction, 3rd degree AV block, syncope


BACKGROUND
AHC
ATP1A3-D801N
R
PR
ST
P
T
Q
S
QT
Repolarization abnormalities
Ventricular arrhythmias
Sinus node dysfunction
METHODS
QT
HR
QTc
HR
IAHCRC
RESULTS
QT
HR
QTc
HR
ATP1A3-D801N
Freedom from Sinus Node Dysfunction
Healthy
ATP1A3
100
80
60
40
20
0
10
20
30
40
50
Age (years)
Sinus Node Dysfunction
Bradycardia
Abnormal QT and QTc Dynamics
Risk of ventricular arrhythmia in ATP1A3-D801N